Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials
- 18 November 2020
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (2) , 517-523
Abstract
BACKGROUND/OBJECTIVES: Accurate estimates of clinically important difference (CID) are required for interpreting the clinical importance of treatments to improve physical function, but CID estimates vary in different disease populations. We determined the CID for two common measures of walking ability in mobility‐limited older men. Design: Longitudinal, multisite placebo‐controlled trial. Setting/Participants: Men enrolled in the Testosterone Trials who had self‐reported mobility limitation and gait speed less than 1.2 m/second (n = 429). Testosterone‐ and placebo‐allocated participants were combined for this study. RESULTS: Mean changes from baseline, adjusting for time‐in‐intervention and site, were 29.6, 13.2, 12.5, −2.4, and −32.6 m for 6MWD, and 15.4, 7.2, 2.1, −3.4, and −7.2 for PF10 in men who reported their mobility was “very/much better,” “little better,” “no change,” “little worse,” or “much worse,” respectively. CID estimates using regression, ROC, and eCDF varied from 5.0–29.6 m for 6MWD, and 5.0–15.2 points for PF10. CONCLUSION: CID estimates vary by the population studied and by the method and precision of measurement. Increases of 16 to 30 m for 6MWD and 5 to 15 points for PF10 over 12 months appear to be clinically meaningful in mobility‐limited, older hypogonadal men. These CID estimates may be useful in the design of efficacy trials of therapies to improve physical function.Keywords
Funding Information
- AbbVie
- National Institute on Aging (U01 AG030644)
This publication has 31 references indexed in Scilit:
- Clinical Meaningfulness of the Changes in Muscle Performance and Physical Function Associated With Testosterone Administration in Older Men With Mobility LimitationThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Meaningful Gait Speed Improvement During the First 60 Days Poststroke: Minimal Clinically Important DifferencePhysical Therapy, 2010
- Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Updating the Minimal Important Difference for Six-Minute Walk Distance in Patients With Chronic Obstructive Pulmonary DiseaseArchives of Physical Medicine and Rehabilitation, 2010
- Interpretation of treatment changes in 6-minute walk distance in patients with COPDEuropean Respiratory Journal, 2008
- Meaningful Change and Responsiveness in Common Physical Performance Measures in Older AdultsJournal of the American Geriatrics Society, 2006
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain, 2001
- Reference Equations for the Six-Minute Walk in Healthy AdultsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Interpreting Small Differences in Functional Status: The Six Minute Walk Test in Chronic Lung Disease PatientsAmerican Journal of Respiratory and Critical Care Medicine, 1997
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992